Varilrix - chickenpox vaccine

Varilrix price

Chickenpox is a highly contagious infectious disease caused by a virus from the herpes virus family. The varicella zoster virus, when it first enters the human body, causes the picture of “chickenpox”. The chickenpox virus “settles” in the nerve plexuses for life. And when the immune system weakens (usually in old age or with severe concomitant diseases), it becomes more active, causing herpes zoster. In childhood, the disease often progresses favorably, but in adults it is much more difficult to tolerate, and bacterial complications are more often observed. The varicella zoster virus poses a particular danger to pregnant women and the fetus.

Where to get vaccinated against chickenpox in Moscow?

At the Miracle Doctor clinic, you can vaccinate children and adults against chickenpox using the drug Varilrix: the vaccine from a trusted European manufacturer will allow you to develop lasting immunity to the infection. Don’t miss the opportunity to protect yourself and your loved ones from contracting the virus, especially since this disease is much more severe in adulthood than in childhood.

Call and make an appointment with a therapist or pediatrician at our clinic by phone or on the website.

Emergency prevention

Vaccination is carried out once with 1 dose of vaccine (0.5 ml) during the first 96 hours after contact (preferably within the first 72 hours). If the disease does not develop, then re-vaccination is carried out after 6-8 weeks.

Clinical studies have shown the high effectiveness of the Varilrix® vaccine. The rate of seroconversion (development of immunity) in healthy children aged 12 months to 12 years inclusive, determined 6 weeks after vaccination, exceeded 98% and persisted for at least 7 years after vaccination.

The seroconversion rate measured in children aged 13 years after two doses of vaccination was 100% and was maintained for at least 1 year.

Clinical studies have shown that the majority of vaccinated people who were subsequently in contact with sick people are either not susceptible to infection or experience a much milder form of the disease (fewer rashes, no fever).

To ensure that the seroconversion rate is as high as possible, since the end of 2012, the Varilrix® vaccine has been used with booster vaccination at all ages, which prevents the occurrence of so-called “breakthrough chickenpox” (an outbreak of chickenpox in vaccinated children).

Benefits of the VARILRIX vaccine

• In all healthy children aged 9 months to 12 years inclusive, six weeks after vaccination, a high level of protection is determined, which persists for at least 7 years after vaccination.
• All children over the age of 13 after two doses of vaccination have a pronounced level of protection that lasts for at least one year.
• Even 1 dose of the vaccine is effective in preventing 81% of all disease-related hospitalizations in children and 87% of outpatient visits to the doctor. Administration of the 2nd dose effectively prevents cases of chickenpox infection.
• The majority of vaccinated people who were subsequently in contact with sick people are either not susceptible to infection or experience a much milder form of the disease (fewer rashes, no fever).

Using Varilrix in combination with other vaccines

The Varilrix® vaccine can be administered simultaneously with all drugs from the national preventive vaccination calendar on the same day, in different parts of the body, with the exception of the BCG vaccine and the rabies vaccine (rabies vaccination).

The use of the Varilrix® vaccine in combination with other vaccinations does not affect their immunogenicity (ability to develop immunity). Tolerability of vaccines does not deteriorate, and the number of adverse reactions does not increase.

Administering several vaccines on the same day does not place an excessive burden on the immune system.

Administration of the Varilrix® vaccine is possible no earlier than 3 months after the administration of immunoglobulins or after blood transfusion.

Varilrix®

Live attenuated vaccine for the prevention of chickenpox.

Administration of the Varilrix® vaccine causes the production of antibodies to the varicella zoster virus, providing specific protection against this infection.

Immunological effectiveness

Healthy subjects

The seroconversion rate in healthy children aged 9 months to 12 years inclusive, determined 6 weeks after vaccination, exceeded 98% and persisted for at least 7 years after vaccination.

The seroconversion rate measured in children aged 13 years after two doses of vaccination was 100% and was maintained for at least 1 year.

Clinical studies have shown that the majority of vaccinated people who were subsequently in contact with sick people are either not susceptible to infection or experience a much milder form of the disease (fewer rashes, no fever). One study also demonstrated 100% protection against standard clinical manifestations of chickenpox and 88% protection against all manifestations of Varicella virus infection (measured as at least one rash).

High-risk patients

Chickenpox is an important risk factor that worsens the course and prognosis of existing severe disease in the following groups of patients:

— patients with acute leukemia;

- patients receiving immunosuppressant therapy, including the use of corticosteroids;

— patients who are planning to undergo a transplant operation;

- patients suffering from severe chronic diseases, such as metabolic and endocrine disorders, chronic lung and cardiovascular diseases, cystic fibrosis and neuromuscular disorders can also be factors that worsen the prognosis for chickenpox;

- healthy people who are in close contact with sick people or high-risk groups, who have not had chickenpox and have not been previously vaccinated.

Patients from the above groups receiving immunosuppressant therapy (including the use of corticosteroids) for malignant solid tumors or for severe chronic diseases (renal failure, autoimmune diseases, collagen diseases, severe bronchial asthma) are predisposed to severe chickenpox.

In high-risk patients, the seroconversion rate is 80%, and in patients with leukemia the rate is approximately 90%.

In high-risk patients, periodic determination of antibody titers to the varicella zoster virus is recommended to decide on the need for revaccination.

One study found that the incidence of chickenpox among patients with leukemia was lower in vaccinated patients than in unvaccinated patients who were naturally infected.

Transmission of vaccinia virus between immunocompromised siblings has been reported, but skin manifestations in infected children were mild.

Adverse reactions

Reactions to the Varilrix® vaccine are rare and most often easily tolerated. They are divided into local and general.

Local reactions: pain and redness at the injection site.

General reactions: increased body temperature to subfebrile levels, lymphadenopathy (swelling of the lymph nodes), weakness, malaise. A rash similar to chickenpox may appear. The rash is not abundant and rarely develops into blisters.

Most often, such reactions do not require special treatment; symptomatic therapy is carried out.

On average, the reactogenicity of the vaccine upon administration of the second dose (re-vaccination) does not exceed the reactogenicity of the first dose. There were also no differences in the safety profile of the vaccine between people with and without immunity to chickenpox.

Possible side effects

Local reactions occur rarely: pain and redness at the injection site.

General reactions occur extremely rarely: increased body temperature to low-grade levels (rectal ≥ 38°C, in the armpit or oral cavity: ≥ 37.5°C), lymphadenopathy, weakness, malaise. A rash similar to chickenpox may appear. The rash is not abundant and rarely develops into blisters. In isolated cases, absolutely extremely rarely, vaccinated people may develop fainting or clonic-tonic convulsions within 15 minutes after vaccination.

Varilrix should be used with caution in cases of thrombocytopenia or blood coagulation disorders, since bleeding may occur during intramuscular administration.

Come get vaccinated at MAMARADA. A full range of vaccines for children and adults, family vaccinations - at a special price!

Contraindications for use

• primary or acquired immunodeficiency (developed as a result of leukemia, lymphoma, clinical manifestations of HIV infection, use of immunosuppressants, including high-dose corticosteroid therapy), as well as in the presence of other signs of cellular immunodeficiency;
• acute infectious and non-infectious diseases, exacerbation of chronic diseases are temporary contraindications for vaccinations; for mild ARVI and acute intestinal diseases, vaccinations are carried out immediately after the temperature has normalized;
• pregnancy or planned pregnancy within 3 months;
• lactation period (breastfeeding);
• hypersensitivity to any component of the vaccine (including neomycin);
• symptoms of hypersensitivity to previous administration of the Varilrix® vaccine.

The vaccine is contraindicated for use during pregnancy or planned pregnancy (within 3 months) and during breastfeeding.

Contraindications

Only a doctor can decide whether Varilrix is ​​suitable for vaccination

Varilrix is ​​contraindicated if you have a history of an allergic reaction to any component of the vaccine.

Varilrix vaccination is contraindicated in the following cases:

• Hypersensitivity to any component of the vaccine, including neomycin; symptoms of hypersensitivity to previous administration of chickenpox vaccine.
• Severe humoral or cellular immunodeficiencies, such as: primary or acquired immunodeficiency (developed as a result of leukemia, lymphoma, blood dyscrasia, clinical manifestations of HIV infection, use of immunosuppressants, including high-dose corticosteroid therapy), defined by the number of lymphocytes - less than 1200/mm3, and in the presence of other signs of cellular immunodeficiency.
• Acute infectious and non-infectious diseases, exacerbation of chronic diseases are temporary contraindications for vaccinations; for mild ARVI and acute intestinal diseases, vaccination is carried out immediately after the temperature has normalized.
• Pregnancy or planned pregnancy within 1 month after vaccination. Breastfeeding period.

additional information

For emergency prevention, the vaccine can be used in the first 96 hours. Time is counted not from the moment the patient is diagnosed, but from the moment of last contact with the patient with chickenpox.

The Varilrix® vaccine protects only against chickenpox and does not protect against other diseases accompanied by skin lesions and other diseases caused by viruses of the herpes family.

Women of childbearing age are advised to protect themselves from pregnancy for 1 month before vaccination and 2 months after vaccination.

Indications for vaccination Varilrix

Varilrix is ​​used to protect against chickenpox. It is especially important to vaccinate patients at risk in a timely manner:

• persons with diagnosed leukemia (blood diseases);
• people taking immunosuppressants;
• in preparation for transplantation;
• persons with severe chronic diseases of internal organs.

For these people, infection with the chickenpox virus is extremely undesirable, because infection can cause serious complications and dramatically worsen the course of the disease. The Varilrix vaccination can also be used as an emergency prophylaxis against chickenpox if the patient has been in contact with an active carrier of the infection. Emergency chickenpox vaccination for adults is given as a single injection of the drug within 3 days after contact with the patient.

How is vaccination carried out?

Vaccination is carried out in a vaccination room, in compliance with all sanitary requirements. All drugs are certified. A certificate for the drug is provided upon request.

Without reminders, before vaccination, the medical worker must show the drug and the expiration date of the vaccine.

Only sterile and disposable instruments are used. The vaccination must be carried out using disposable medical gloves.

On the day of vaccination, the child is examined by a pediatrician and the temperature is measured. In the absence of contraindications, vaccination is carried out. Information about the vaccination performed is entered into the card, vaccination certificate, and detailed recommendations for caring for the child in the post-vaccination period are given.

Before vaccination, the doctor will answer all your questions. Be sure to bring information about previous vaccinations to your appointment!

Please note that vaccination of a child, Mantoux test, Diaskintest can only be carried out in the presence of parents or legal representatives of the child (guardians), or if the accompanying person has a NOTARIZED power of attorney to carry out the manipulation (indicating the drug planned for administration) . Otherwise, vaccination will be denied. We comply with the laws of the Russian Federation.

Only here!